宁波健世科技股份有限公司
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | FutureX | futurexcap... |
Mentions in press and media 12
| Date | Title | Description |
| 30.10.2025 | Jenscare released its multi-product portfolio's, including LuX-Valve Plus TRINITY study, JensClip and Ken-Valve, remarkable clinical outcomes at TCT 2025 in the U.S. | BEIJING, Oct. 30, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-V... |
| 09.10.2025 | LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect | BEIJING, Oct. 9, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, r... |
| 01.09.2025 | Jenscare Announces 2025H1 Interim Results | BEIJING, Sept. 1, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases, a... |
| 01.09.2025 | Jenscare, releases 2025H1 interim results | BEIJING, Sept. 1, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with TTVR breakthroughs, achieved milestones in its product portfolio ... |
| 03.06.2025 | Jenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025 | BEIJING, June 3, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Val... |
| 01.11.2024 | A New Dawn for Heart Health: The LuX-Valve Plus Breakthrough | In the world of cardiology, innovation is the lifeblood that keeps patients hopeful. The recent unveiling of the one-year outcomes from the LuX-Valve Plus TRAVEL II study at the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT... |
| 01.11.2024 | The 1-Year Follow-up Results of LuX-Valve Plus were Officially Released at TCT 2024 | WASHINGTON, Nov. 1, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases ... |
| 31.10.2024 | The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024 | WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases... |
| 29.08.2024 | Jenscare's Heartfelt Progress: A Glimpse into 2024H1 Results | In the bustling heart of Beijing, Jenscare Scientific Co., Ltd. is making waves in the medical device industry. This innovative company is dedicated to transforming the landscape of interventional treatments for structural heart diseases. T... |
| 28.08.2024 | Jenscare, with innovative TTVR, releases 2024H1 interim results | BEIJING, Aug. 28, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases wi... |
Show more